Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/55/2/42 |
| _version_ | 1797706534410518528 |
|---|---|
| author | Maria Maddalena Simile Paola Bagella Gianpaolo Vidili Angela Spanu Roberto Manetti Maria Antonietta Seddaiu Sergio Babudieri Giordano Madeddu Pier Andrea Serra Matteo Altana Panagiotis Paliogiannis |
| author_facet | Maria Maddalena Simile Paola Bagella Gianpaolo Vidili Angela Spanu Roberto Manetti Maria Antonietta Seddaiu Sergio Babudieri Giordano Madeddu Pier Andrea Serra Matteo Altana Panagiotis Paliogiannis |
| author_sort | Maria Maddalena Simile |
| collection | DOAJ |
| description | Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the early stages. This fact, along with the poor results of the local and systemic therapies currently employed, is responsible for the poor outcome of CCA patients and strongly supports the need for novel therapeutic agents and strategies. In recent years, the introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the genetic pathophysiology of CCA and, consequently, for the identification and evaluation of new treatments tailored to the molecular features or alterations progressively elucidated. In this review article, we describe the potential targets under investigation and the current molecular therapies employed in biliary tract cancers. In addition, we summarize the main drugs against CCA under evaluation in ongoing trials and describe the preliminary data coming from these pioneering studies. |
| first_indexed | 2024-03-12T05:53:43Z |
| format | Article |
| id | doaj.art-a834510c0d2248399865e98a8605f021 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T05:53:43Z |
| publishDate | 2019-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-a834510c0d2248399865e98a8605f0212023-09-03T04:54:57ZengMDPI AGMedicina1010-660X2019-02-015524210.3390/medicina55020042medicina55020042Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical TrialsMaria Maddalena Simile0Paola Bagella1Gianpaolo Vidili2Angela Spanu3Roberto Manetti4Maria Antonietta Seddaiu5Sergio Babudieri6Giordano Madeddu7Pier Andrea Serra8Matteo Altana9Panagiotis Paliogiannis10Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, ItalyCholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the early stages. This fact, along with the poor results of the local and systemic therapies currently employed, is responsible for the poor outcome of CCA patients and strongly supports the need for novel therapeutic agents and strategies. In recent years, the introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the genetic pathophysiology of CCA and, consequently, for the identification and evaluation of new treatments tailored to the molecular features or alterations progressively elucidated. In this review article, we describe the potential targets under investigation and the current molecular therapies employed in biliary tract cancers. In addition, we summarize the main drugs against CCA under evaluation in ongoing trials and describe the preliminary data coming from these pioneering studies.https://www.mdpi.com/1010-660X/55/2/42cancerbiliary treecholangiocarcinomamolecular pathwaysgenomicstargeted therapies |
| spellingShingle | Maria Maddalena Simile Paola Bagella Gianpaolo Vidili Angela Spanu Roberto Manetti Maria Antonietta Seddaiu Sergio Babudieri Giordano Madeddu Pier Andrea Serra Matteo Altana Panagiotis Paliogiannis Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials Medicina cancer biliary tree cholangiocarcinoma molecular pathways genomics targeted therapies |
| title | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| title_full | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| title_fullStr | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| title_full_unstemmed | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| title_short | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| title_sort | targeted therapies in cholangiocarcinoma emerging evidence from clinical trials |
| topic | cancer biliary tree cholangiocarcinoma molecular pathways genomics targeted therapies |
| url | https://www.mdpi.com/1010-660X/55/2/42 |
| work_keys_str_mv | AT mariamaddalenasimile targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT paolabagella targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT gianpaolovidili targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT angelaspanu targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT robertomanetti targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT mariaantoniettaseddaiu targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT sergiobabudieri targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT giordanomadeddu targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT pierandreaserra targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT matteoaltana targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials AT panagiotispaliogiannis targetedtherapiesincholangiocarcinomaemergingevidencefromclinicaltrials |